about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

7 years ago
R&D
Pharma

J&J joins block­buster HIV com­bo race with new­ly ap­proved 4-in-1 pill

7 years ago
Pharma

Boom time: Ru­bius, Cri­net­ics find big sup­port in up­sized IPOs to­tal­ing $343M raise

7 years ago
Financing
Startups

Pre-rev­enue vac­cine de­vel­op­er CanSi­no lines up at a buzzing HKEX

7 years ago
Financing
China

6 Di­men­sions backs Lyv­gen's $30M B round; No­var­tis hands off glob­al rights to IL-2 drug

7 years ago
News Briefing

On its way to mak­ing Hong Kong his­to­ry, As­cle­tis eyes $457M haul in GIC-backed IPO

7 years ago
Financing
China

Fast-grow­ing As­cen­t­age has big plans for its lat­est $150M raise -- but what about the IPO?

7 years ago
Financing
China

FDA ex­perts back GSK's new malar­ia drug; Sang­amo's new­ly mint­ed CTO jumps to biotech up­start

7 years ago
News Briefing

Chas­ing Bio­gen, the Pli­ant crew banks a $62M round to fu­el their shot at fi­bro­sis tar­gets

7 years ago
Financing

Guard­ing against a night­mare sce­nario, FDA ap­proves new drug to counter small­pox out­break

7 years ago
Pharma

George Golumbeski's first stop out of Cel­gene: Grail; Roivant taps Genen­tech vet Myr­tle Pot­ter for op­er­a­tions role

7 years ago
Peer Review

Gen­mab puts down $54M for im­munother­a­py col­lab­o­ra­tion — ready to spend mil­lions more

7 years ago
Pharma

Bris­tol-My­ers Squib­b's Op­di­vo/Yer­voy com­bo scores col­orec­tal can­cer OK; For­mer Ake­bia, Mer­ri­mack staffers found ...

7 years ago
News Briefing

For­bion rais­es $316M to tap the po­ten­tial of Eu­ro­pean biotech plays

7 years ago
Financing

Chi­na's Tasly Bio­phar­ma turns a de­vel­op­ment part­ner in­to an in­vestor as it preps Hong Kong IPO

7 years ago
China
Pharma

Genen­tech vet Myr­tle Pot­ter takes a lead­ing role in Vivek Ra­maswamy's fast-mov­ing Vant ops

7 years ago
People
R&D

An­ti­body mak­er Vac­cinex files $46M IPO tout­ing I/O com­bo drug; Replimune shoots for $100M-plus in IPO

7 years ago
News Briefing

Aquinox dis­cards lead drug, chops half of its staff in wake of PhI­II dis­as­ter

7 years ago
R&D

Cash-strapped Reg­u­lus braces for dras­tic down­siz­ing while hit­ting the brakes on lead pro­grams

7 years ago
R&D
Pharma

Ac­celeron poach­es ex-Abl­ynx CMO Robert Zeldin; Deb­o­rah Dun­sire leaves for Lund­beck­'s top job af­ter XTu­it im­plo­sion

7 years ago
Peer Review

That Alzheimer's drug that flunked a PhII? On sec­ond look, Bio­gen/Ei­sai say it's a win­ner

7 years ago
R&D

Take­da posts 'for-sale' sign on com­pa­ny's an­ces­tral home in Os­a­ka in ef­fort to fund Shire buy­out

7 years ago
Deals

An­oth­er IPO fren­zy? Two US biotechs head to Hong Kong for a pub­lic mar­ket de­but

7 years ago
Financing
China

Hong Kong ex­change picks up steam with two biotech IPOs from In­novent, Mi­cuRx

7 years ago
Financing
China
First page Previous page 114115116117118119120 Next page Last page
A service from the Financial Times